We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's NDA for Heart Failure Candidate Gets Priority Review
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has accepted and granted priority review to the new drug application (“NDA”) for its orally soluble guanylate cyclase (sGC) stimulator, vericiguat. The NDA is seeking approval for vericiguat in combination with other therapies to reduce the risk of cardiovascular death and heart failure following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
A decision related to approval of the NDA is expected by Jan 20, 2021 from the FDA. Please note that Merck has developed the candidate in collaboration with its Germany-based partner Bayer (BAYRY - Free Report) .
The NDA was filed based on positive data from the phase III contemporary outcomes study — VICTORIA. Data from the study, announced last year, showed that vericiguat reduced the risk of composite endpoint of heart failure hospitalization or cardiovascular death in such patients compared to placebo.
Merck’s shares have declined 12.6% this year so far against the industry’s increase of 1.2%.
Heart failure affects more than 60 million patients globally. Despite huge progress made on addressing this disease, the cardiovascular event rates are high, creating a huge unmet need for new therapies to reduce the risk of death and hospitalizations. In the United States, currently 6.5 million people suffer heart failure and approximately 40-50% of these have HFrEF, per the press release. Such patients frequently experience deterioration of the disease and an estimated one in five patients with worsening chronic HFrEF expires within two years.
Novartis’ (NVS - Free Report) Entresto is approved to treat HFrEF. Amgen (AMGN - Free Report) and partner Cytokinetics’s pipeline candidate omecamtiv mecarbil is in late-stage development for HFrEF. AstraZeneca’s SGLT2 inhibitor Farxiga was approved for treating HFrEF in May 2020.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Shutterstock
Merck's NDA for Heart Failure Candidate Gets Priority Review
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has accepted and granted priority review to the new drug application (“NDA”) for its orally soluble guanylate cyclase (sGC) stimulator, vericiguat. The NDA is seeking approval for vericiguat in combination with other therapies to reduce the risk of cardiovascular death and heart failure following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
A decision related to approval of the NDA is expected by Jan 20, 2021 from the FDA. Please note that Merck has developed the candidate in collaboration with its Germany-based partner Bayer (BAYRY - Free Report) .
The NDA was filed based on positive data from the phase III contemporary outcomes study — VICTORIA. Data from the study, announced last year, showed that vericiguat reduced the risk of composite endpoint of heart failure hospitalization or cardiovascular death in such patients compared to placebo.
Merck’s shares have declined 12.6% this year so far against the industry’s increase of 1.2%.
Heart failure affects more than 60 million patients globally. Despite huge progress made on addressing this disease, the cardiovascular event rates are high, creating a huge unmet need for new therapies to reduce the risk of death and hospitalizations. In the United States, currently 6.5 million people suffer heart failure and approximately 40-50% of these have HFrEF, per the press release. Such patients frequently experience deterioration of the disease and an estimated one in five patients with worsening chronic HFrEF expires within two years.
Novartis’ (NVS - Free Report) Entresto is approved to treat HFrEF. Amgen (AMGN - Free Report) and partner Cytokinetics’s pipeline candidate omecamtiv mecarbil is in late-stage development for HFrEF. AstraZeneca’s SGLT2 inhibitor Farxiga was approved for treating HFrEF in May 2020.
Merck Co., Inc. Price
Merck Co., Inc. price | Merck Co., Inc. Quote
Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>